TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04386343
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo was used on patients as a control for the doses of CH1701
Study: NCT02327039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tables of Dapagliflozin placebo
Study: NCT02404571
Drug: GDP chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
Study: NCT00964782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will receive a look-alike placebo. Enrolled patients will be randomized to receive Placebo first and then crossed over to receive the opposite intervention, Sildenafil.
Study: NCT00964782
Drug: Placebo 2
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will receive a look-alike placebo. Enrolled patients will receive Placebo, the crossed over intervention from their initial intervention (Sildenafil).
Study: NCT03879837
Drug: Placebo pressurized metered dose inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: no active content
Study: NCT04156698
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is a chemotherapy drug.
Study: NCT02767401
Drug: aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
Study: NCT03084861
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Artificial tears: Lubristil ®~2. Therapeutic Contact lens: Air Optix Night\&Day
Study: NCT05081687
Drug: Folfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU 2400mg/m2; Oxaliplatin 85 mg/m2, Irinotecan 150mg/m2
Study: NCT01244100
Drug: PL2200 fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fed state
Study: NCT02629770
Drug: usual antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: pharmacological studies in patients treated with usual antibiotics, for different types of joint and bone infections
Study: NCT00163059
Drug: NMDA Antagonist, CP-101,606 (traxoprodil)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02550054
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
Study: NCT01051778
Drug: Heparin calcium5,000 U twice daily plus low dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin Calcium 5,000 U twice daily (Cal-Heparine, Amoun Pharmaceutical Co, Egypt) by subcutaneous injection is started when the serum pregnancy test become positive. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID))is started before conception and continued until 36 weeks gestation .
Study: NCT02072200
Drug: Lodotra®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single arm will be received below oral 10mg tablet daily and maximum 10mg/d depending on the clinical symptoms and the patient's response
Study: NCT03778671
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive Levobupivacaine 5% + 1 µg/kg fentanyl
Study: NCT02647866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT00881608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 1 capsule daily for five days
Study: NCT04559113
Drug: Methylprednisolone Injectable Product
Normalized name: methylprednisolone Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. 0.5mg to 1mg/Kg methylprednisolone or equivalent dexamethasone dose (to a maximum of 20mg) given daily x 5 to 7-days or~2. Methylprednisolone 1 mg/kg daily IV for 5 days followed by 40 mg daily x 3 days, followed by 10 mg daily x 2 day.
Study: NCT01872611
Drug: Nepafenac Ophthalmic Suspension, 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01872611
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
Study: NCT04386447
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care (SoC). Standard of Care will comply with the indications of the Emilia-Romagna Region for the treatment of covid-19, and will include the following:~* Oxygen supply or non-invasive ventilation to target peripheral blood saturation \> 94%~* Hydroxychloroquine 200mg b.i.d w/o an initial 1-2 days loading dose of 400 mg bid for 1-2 days (the dose may be reduced in patients with advanced CKD according to local protocols) or remdesivir 200 mg in.v on day 1, followed by a 100 mg q.d.~* Antiretroviral therapy (usually for 5 days) with lopinavir / ritonavir or darunavir / cobicistat is permitted~* Azithromycin 500 mg q.d., usually for 5 days, is permitted in patients with suspected bacterial superinfection, paying particular attention to safety, considering reports of risk of adverse events in association with hydroxychloroquine~* Prophylaxis for deep vein thrombosis~* Steroids are not routinely recommended but may be considered in selected patients.
Study: NCT01537172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match ONO-4053 tablets, dosed in a similar manner to ONO-4053
Study: NCT00660452
Drug: Staloral
Normalized name: aspirin / hydrocodone bitartrate Oral Tablet [Alor]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with Staloral dust mites solution
Study: NCT02519556
Drug: Probiatop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilute one sachet in 100ml of water and take it in every morning, once a day for 6 months.
Study: NCT02519556
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 sachet, once a day for 6 months. Dilute one sachet in 100ml of water and take it in every morning.
Study: NCT05266261
Drug: Ibandronate Oral Tablet
Normalized name: ibandronate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of ibandronate + 24,000 IU of cholecalciferol
Study: NCT00434252
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by IV infusion on the first day of each 3-week cycle
Study: NCT00066456
Drug: Chemosensitization/Potentiation Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02733419
Drug: Optimized background antiretroviral regimen (OB)
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive OB (nucleoside and or non-nucleoside reverse transcriptase inhibitor and protease inhibitor) as per investigator's discretion. Protocol does not specify any particular OB drugs.
Study: NCT02868944
Drug: control group : sequential combined spinal epidural with local anesthetic injection (chirocaine) alone.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03099785
Drug: Placebo t.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning. one matching placebo tablet Afternoon: one matching placebo tablet Evening: one matching placebo tablet
Study: NCT01515358
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01515358
Drug: LY3000328
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01822821
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive up to four doses of IV Acetaminophen (1000mg)every six hours after surgery along with standard PCA (patient controlled) opioids.
Study: NCT01822821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive up to four doses placebo every six hours after surgery along with standard PCA (patient controlled) opioids.
Study: NCT02806895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01235585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses, once a day for 52 weeks
Study: NCT00618501
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00618501
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00618501
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00618501
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01067391
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet administered once per study protocol
Study: NCT01363661
Drug: Coruno
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine 16 mg tablet, per os, once a day
Study: NCT03276143
Drug: BAY1213790
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of BAY1213790 administered as intravenous infusion
Study: NCT03345797
Drug: Testosterone Nasal Gel [Natesto]
Normalized name: testosterone Nasal Gel [Natesto]
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasal gel containing 4.5% w/w testosterone
Study: NCT00163592
Drug: Tissucol®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01363661
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (16 mg tablet, per os; once-daily)
Study: NCT02606461
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02556866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01612013
Drug: Intravenous NAC plus saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine (Flucistein 100 mg/ml, Neo Química, Brazil) was given via IV bolus at a rate of 150 mg/kg in 500 ml dextrose 5% over 60 min immediately before contrast exposure and followed by 50 mg/kg in 500 ml dextrose 5% during the contrast exposure and for 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
Study: NCT01612013
Drug: NAC plus saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.
Study: NCT03635788
Drug: Standard of Care (SOC) Oral ART
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC oral ART regimen must include at least 3 drugs with 2 or more drugs predicted to be fully active, including a boosted protease inhibitor (PI) and/or an integrase strand transfer inhibitor (INSTI)
Study: NCT03635788
Drug: Oral RPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPV 25 mg tablets
Study: NCT03635788
Drug: RPV-LA Loading Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg administered as one 3 mL (900 mg) intramuscular injection in the gluteal muscle
Study: NCT03635788
Drug: RPV-LA Maintenance Dose
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg administered as one 2 mL (600 mg) intramuscular injection in the gluteal muscle
Study: NCT03635788
Drug: CAB-LA Maintenance Dose
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg administered as one 2 mL (400 mg) intramuscular injection in the gluteal muscle
Study: NCT01498874
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
Study: NCT00365417
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m\^2 IV every 21 days x 4 cycles
Study: NCT00365417
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m\^2 IV every 21 days x 4 cycles
Study: NCT00365417
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Following clinical response assessment, 650 mg/m\^2 twice a day (orally), days 1-14 every 21 days x 4 cycles
Study: NCT04274179
Drug: Absence epilepsy medications
Normalized name: BRACELET,MEDICAL ALERT EPILEPSY
Approvals — FDA: no, EMA: no, PMDA: no
Description: At neurologist's discretion. \*OF NOTE\< THIS ARM IS COMPLETED
Study: NCT03150368
Drug: ModraDoc006/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
Study: NCT01365338
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT00851591
Drug: fenugreek
Normalized name: fenugreek
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules 3 times per day with a full glass of water each dose for 7 days
Study: NCT00851591
Drug: Placebo (Psyllium)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules 3 times a day with a full glass of water each dose for 7 days
Study: NCT01313637
Drug: GSK573719/GW642444 125/25mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125/25mcg
Study: NCT06004960
Drug: [14C]CCX168
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT01313637
Drug: GSK573719 125mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125mcg
Study: NCT01313637
Drug: GW642444 25mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mcg
Study: NCT01313637
Drug: Placebo only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03518684
Drug: Natalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: A specially-designed sterile obstetric gel (Natalis) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that has a purely physical activity. It contains propylene glycol, glycerol, sodium chloride, xanthan gum, hydroxyethylcellulose and water.~Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child using the sterile obstetric gel applicator without any manipulation or massaging. Additional obstetric gel will be added 15-30 minutes after rupture of the membranesOnce the head of the child is visible, the mouth and nose region will be wiped clean. A dry towel will be used to liberate the child in order to prevent the child from slipping
Study: NCT01304147
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of saline intranasal
Study: NCT03416127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.
Study: NCT04332276
Drug: A-dopamine
Normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the phase 1 (titration), it is planned to increase dopamine by maximum 0.25 mg per hour over the daytime period, which corresponds to a maximum increase of 4.5 mg per day (based on the 18 hours of the daytime period, since nocturnal needs are much less important).~Then, depending on tolerance and efficacy, conservative titration will be continued for a target dose of 30-87 mg per day.~During the phase 2 (efficacy), the treatment will be maintained at the minimum effective dose, planned between 30 and 87 mg per day, for 30 days.
Study: NCT04332276
Drug: optimized oral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will received his usual dopaminergic treatment.
Study: NCT02222636
Drug: Normal saline,1 milliliter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline,1 milliliter, 20 minutes before anaesthetic induction
Study: NCT02222636
Drug: Anesthesia maintenance, 2%~3% sevoflurane,fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2%\~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion
Study: NCT02630888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to this group will receive a unit dosage identical to that contains 15 mg of memantine during the first week (V0); all have the dose of the placebo (similar to memantine) increased on the second week (V1) in two divided doses of a unit dosage identical to that contains 15 mg of memantine
Study: NCT03271697
Drug: Astragalus Membranaceus
Normalized name: Astragalus membranaceus
Approvals — FDA: no, EMA: no, PMDA: no
Description: This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.
Study: NCT03271697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: as a comparator comparing with AM group
Study: NCT02054156
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months
Study: NCT02054156
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months
Study: NCT02054156
Drug: Tobramycin solution for inhalation
Normalized name: tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
Study: NCT03873532
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is given at 1250 mg/m2 by oral administration twice a day (BID, one dose each in the morning and evening, with a total dose of 2500 mg/m2 per day) for 2 weeks followed by 1 week of drug interruption. Each course of treatment will last 3 weeks. Capecitabine tablets should be swallowed with water within 30 minutes after a meal.
Study: NCT00516646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: bid
Study: NCT00706797
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02715531
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin 200 mg/m\^2 L-isomer form or 400 mg/m\^2 D,L-racemic form will be administered IV over 120 (± 15) minutes, q2w.
Study: NCT02715531
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine may be administered after 6 months at the discretion of the investigator (range of 650-1000 mg/m\^2) twice daily on Days 1-4 of a 21-day cycle.
Study: NCT03537287
Drug: 17 alpha hydroxyprogestrone caproate
Normalized name: 17-alpha-hydroxy-progesterone caproate
DrugBank: Hydroxyprogesterone caproate (DB06789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg of 17 alpha hydroxyprogestrone caproate weekly
Study: NCT01746680
Drug: Tacrolimus with Methotrexate
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus 1 mg for 0\~week4, 2mg for week4\~week8, 3mg for week8\~week24 with MTX ≤20mg/week
Study: NCT01586325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo administered once daily as monotherapy for 5 days.
Study: NCT03621553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic ergocalciferol 50,000 units
Study: NCT02423408
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT01687699
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01518257
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.
Study: NCT00512408
Drug: testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04100473
Drug: Inhaled Human Insulin
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance 501 administered using the Dance 501 Inhaler
Study: NCT01102478
Drug: losartan potassium / hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg / 25 mg tablet
Study: NCT01287065
Drug: Placebo AM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation powder
Study: NCT01287065
Drug: Placebo PM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation powder
Study: NCT03227796
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous infusion
Study: NCT00537485
Drug: SPM 962
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal application, 1 time per day
Study: NCT04870164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One administration at day 1 by infusion.
Study: NCT00537485
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal application, 1 time per day
Study: NCT00908232
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg, p.o daily, days 1, 8 and 15 for cycles 5 to 8 cycles
Study: NCT01148966
Drug: aminolevulinic acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00448864
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01600703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral, single dose